Sponsor: BioAlta, LLC
Sponsor Study ID: BA3011-002
Study Title: A Phase 2 Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non Small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on or Are Intolerant to a PD 1/L 1, EGFR, or ALK Inhibitor
CTO #: 103390
NCT Number: NCT04681131
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Lung
Study Objectives: To assess antitumor activity of BA3011 alone and in combination with nivolumab. To assess the safety of BA3011 alone and in combination with nivolumab.